GlassScriptPhysician profile
Gregory Houston Miller
NPI 1063445989
$7,650.84
in general payments reported to CMS, 2019-2025
33 companies · $1,013 in 2025
The $1,013 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $780 · 2021: $810 · 2022: $1,062 · 2023: $1,228 · 2024: $1,641 · 2025: $1,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,881.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,375.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $757.73 | 2019-2025 | Brilinta, Wainua, Farxiga |
| Medtronic, INC. | $735.71 | 2021-2025 | Corevalve Evolut R, Micra, Azure Xt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $686.71 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $585.85 | 2019-2025 | Lifevest |
| Irhythm Technologies, INC. | $495.78 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $369.10 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $337.14 | 2020-2024 | Xience Skypoint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.78 | 2019-2025 | Jardiance |
| Amgen INC. | $294.47 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $276.86 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $232.26 | 2024-2025 | Wegovy, Ozempic |
| Pfizer INC. | $176.17 | 2019-2024 | |
| Abiomed | $166.68 | 2023-2024 | Impella |
| Sanofi-Aventis U.S. LLC | $130.33 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $106.70 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.50 | 2025 | |
| Lundbeck LLC | $78.05 | 2019-2020 | |
| Biosense Webster, INC. | $68.95 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $68.02 | 2023-2024 | Inpefa |
| Cardiva Medical, INC. | $44.52 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Inari Medical, INC. | $32.38 | 2022 | |
| Esperion Therapeutics, INC. | $29.91 | 2021-2023 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $29.29 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $22.26 | 2023 | Uptravi, Opsumit |
| Bridgebio Pharma, INC. | $21.60 | 2025 | Attruby |
| Werfen USA LLC | $20.14 | 2023 | |
| Chiesi USA, INC. | $19.00 | 2020 | |
| Livanova USA, INC. | $17.90 | 2020 | |
| Cardiovascular Systems INC. | $17.56 | 2021 | |
| Amarin Pharma, INC. | $16.90 | 2021 | |
| Philips North America LLC | $16.56 | 2025 | Coronary Other |
| Elutia, INC. | $14.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.